CD19 and neoplasm: All tumor types treated with this therapy had a high initial complete response (CR) rate, but long-term disease-free survival can still be improved [4]The therapeutic success of CAR T cells is sometimes discrepant as it is shaped by several factors, boosting the conduction of a comparative analysis to address the global impact of in vivo and ex vivo conditions that influence CD19 CAR T cell performance in clinical trials.